Skip to main content

Myers Scott Dunseth

No open-market purchases or sales filed in the past year.

Current role at each company

Show 1 more company
  • Trillium Therapeutics Inc.Directoras of Nov 19, 2021

Open-market trades in the past year

Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.

Bought
–
0 filings
Sold
–
0 filings
Net
–
Bought minus sold
Companies
0
With open-market trades

Trades

Every Form 4 that lists Myers Scott Dunseth as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.

DVAX Dynavax Technologies Corp

Director1 trade

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 25, 2025 (view filing)Aug 223 daysMyers Scott DunsethDirectorPPurchase+3.80K$10.82+$41.1K+12.2%35.0K after

ZNTL Zentalis Pharmaceuticals, Inc.

Director1 trade

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Apr 30, 2025 (view filing)Apr 30Same dayMyers Scott DunsethDirectorPPurchase+21.0K$1.40+$29.4K+8.1%281.2K after

VRDN Viridian Therapeutics, Inc.

Chief Executive Officer2 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Apr 12, 2023 (view filing)Apr 12Same dayMyers Scott DunsethChief Executive OfficerPPurchase+4.00K$25.37+$101.5K+1.6%259.5K after
Mar 13, 2023 (view filing)Mar 13Same dayMyers Scott DunsethChief Executive OfficerPPurchase+5.50K$29.15+$160.3K+2.2%255.5K after